NCT04699123View on ClinicalTrials.gov

The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

February 4, 2021

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Advanced Non-small Cell Lung Cancer
Interventions
DRUG

NC318 800 mg

NC318 will be given intravenously (IV) weekly for 8 doses and then every 2 weeks for patients receiving combination therapy treatment or weekly for patient receiving NC318 in monotherapy.

DRUG

NC318 400 mg

NC318 will be given intravenously (IV) every 2 weeks.

DRUG

Pembrolizumab

Pembrolizumab 200 mg will be given IV every 3 weeks

Trial Locations (1)

06492

Yale University, New Haven

Sponsors

Collaborators (1)

NextCure, Inc.
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

NextCure, Inc.

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Yale University

OTHER

NCT04699123 - The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter